We have located links that may give you full text access.
Short-term Outcomes of Xen 45 Gel Stent ab Interno Versus ab Externo Transconjunctival Approaches.
Journal of Glaucoma 2023 March 14
PRECIS: Ab externo transconjunctival placement of the Xen 45 gel stent offers a faster surgical approach and more rapid visual recovery with similar pressure-lowering and complication rates when compared with implantation by the ab interno approach.
PURPOSE: Compare outcomes of closed conjunctival Xen-45 implantation techniques: ab interno versus ab externo transconjunctival.
METHODS: Single-center, retrospective study of 70 patients undergoing Xen-45 implantation between 2017-2020. Group 1 (n=29) had ab interno placement, Group 2 (n=41) had transconjunctival ab externo placement. Primary outcome measures were intraocular pressure (IOP) and medication use. Secondary measures were bleb revision rates, surgical time, time to return to baseline visual acuity, and complication rates.
RESULTS: Group 1, pre-operative IOP was 22.8±7.5 mmHg on 3.8±0.9 IOP-lowering medications and the post-operative IOP at last follow up was 11.6±2.8 mmHg on 1.6±1.3 medications. Group 2, pre-operative IOP was 25.6 mmHg±7.8 mmHg on 3.7±1.1 medications and the post-operative IOP at last follow up was 12.4±3.6 mmHg on 1.5±1.3 medications. There was no difference in post-operative IOP or medications between the two groups (P<0.05). The average surgical time for Group 2 was 25±6.5 minutes to 37±7.3 minutes for Group 1 (P<0.001). Group 2 showed 88% of patients returning to baseline visual acuity at week 2 compared to 66% in Group 1 (P<0.05). Bleb revision rates, failure rates, and complication rates were comparable between both groups (P>0.05).
CONCLUSION: IOP, medication use, complications, bleb revision rates, and failure rates were similar between ab interno and ab externo transconjunctival approaches. The ab externo group had faster surgical times and post-operative visual recovery despite higher number of patients with previous glaucoma procedures.
PURPOSE: Compare outcomes of closed conjunctival Xen-45 implantation techniques: ab interno versus ab externo transconjunctival.
METHODS: Single-center, retrospective study of 70 patients undergoing Xen-45 implantation between 2017-2020. Group 1 (n=29) had ab interno placement, Group 2 (n=41) had transconjunctival ab externo placement. Primary outcome measures were intraocular pressure (IOP) and medication use. Secondary measures were bleb revision rates, surgical time, time to return to baseline visual acuity, and complication rates.
RESULTS: Group 1, pre-operative IOP was 22.8±7.5 mmHg on 3.8±0.9 IOP-lowering medications and the post-operative IOP at last follow up was 11.6±2.8 mmHg on 1.6±1.3 medications. Group 2, pre-operative IOP was 25.6 mmHg±7.8 mmHg on 3.7±1.1 medications and the post-operative IOP at last follow up was 12.4±3.6 mmHg on 1.5±1.3 medications. There was no difference in post-operative IOP or medications between the two groups (P<0.05). The average surgical time for Group 2 was 25±6.5 minutes to 37±7.3 minutes for Group 1 (P<0.001). Group 2 showed 88% of patients returning to baseline visual acuity at week 2 compared to 66% in Group 1 (P<0.05). Bleb revision rates, failure rates, and complication rates were comparable between both groups (P>0.05).
CONCLUSION: IOP, medication use, complications, bleb revision rates, and failure rates were similar between ab interno and ab externo transconjunctival approaches. The ab externo group had faster surgical times and post-operative visual recovery despite higher number of patients with previous glaucoma procedures.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app